Pharma major Lupin Limited (Lupin) announced the launch of Mycophenolate Mofetil Capsules USP, 250 mg. Lupin's alliance partner Concord Biotech Limited (Concord) had received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.
Mycophenolate Mofetil Capsul es USP, 250 mg, is the generic version of Roche's CeiiCept®. Mycophenolate Mofetil Capsules are an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants, and should be used in combination with other immunosuppressants.
Mycophenolate Mofetil Capsules USP, 250 mg, had annual sales of approximately USD 53 million in the U.S. (IQVIA MAT August 2019).
Shares of LUPIN LTD. was last trading in BSE at Rs.686.6 as compared to the previous close of Rs. 701.05. The total number of shares traded during the day was 39875 in over 1320 trades.
The stock hit an intraday high of Rs. 708.05 and intraday low of 684.65. The net turnover during the day was Rs. 27709070.